Analysis Of Research Status of Antibody-Drug Conjugate in The Treatment of Colorectal Cancer

As the most frequent malignant tumors in the digestive system, Colorectal Cancer (CRC) has a high incidence and mortality in recent years. Asymptomatic or asymptomatic symptoms are not obvious in CRC patients due to early clinical manifestations. The current treatment plan for CRC is a comprehensive treatment plan based on surgery, but about 30% of patients still have recurrence and metastasis and lead to death after receiving traditional treatment. The treatment of CRC is still being optimized, and more scientists are constantly investing in the discovery and development of novel medications. With the deepening of research and the improvement of clinical trial data, antibody-drug conjugate (ADC) targeting specific targets have gradually shown great potential therapeutic effects. In this paper, the basic principle of ADC, the research status of ADC for CRC and the application limitations of ADC drugs are reviewed. The development of ADC has brought new hope for the treatment of CRC patients, but the toxicity and drug resistance of ADC is still a great challenge to limit the efficacy of ADC. At present, how to combine ADC with personalized treatment of patients, effectively reduce toxicity, and find the next generation of high efficiency and low toxicity is the development direction of ADC.